Sign in3 stories
The company signed its underwriting agreement and set final terms for the stock and warrant offering that priced August 31, 2026, closing September 2.
SEC filing (3)
Updated interim data from the PYNNACLE Phase 2 pivotal trial support plans for a first-quarter 2027 NDA submission seeking accelerated approval.
SEC filing
The company finished enrolling ovarian cancer patients for its Phase 2 monotherapy primary analysis and reported $79.4 million in cash as of June 30, 2026.
SEC filing